کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3332532 | 1213098 | 2009 | 4 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Efficacy and safety of boosted atazanavir in HIV-infected, ARV-naive patients - results from 48/96 weeks Castle study
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
ایمونولوژی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Antiretroviral regimens based on human immunodeficiency virus-1 protease inhibitors are the cornerstone of combination antiretroviral therapy because of their antiviral efficacy and high genetic barrier. Protease inhibitor - containing regimens are complicated by a number of side effects, mainly diarrhea, dyslipidemia, an increased risk of myocardial infarction, diabetes and lipodystrophy. Atazanavir (ReyatazTM) is the first, originally designed as once-daily HIV-1 protease inhibitor that offers a more convenient and safer PI-containing management of HIV infection. The antiviral efficacy of atazanavir has been proven in both treatment-experienced and treatment-naive patients. In July 2008 boosted atazanavir has received registration for use in antiretroviral-naive HIV-infected population. This specific registration was based on results from 48 weeks of the Castle (BMS AI424138) study.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: HIV & AIDS Review - Volume 8, Issue 1, 2009, Pages 5-8
Journal: HIV & AIDS Review - Volume 8, Issue 1, 2009, Pages 5-8
نویسندگان
Ewa Siwak, Tomasz Mikula, Wojciech StaÅczak, Alicja Wiercinska-Drapalo,